Bavarian Nordic Reports P-III Clinical Trial Results of CHIKV VLP (PXVX0317) for Chikungunya Virus Vaccine in Adults and Adolescen...
August 7, 2023
Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine
February 15, 2023
Bavarian Nordic Reports the First Patient Dosing in P-III (VANIR) Trial for the Treatment of Respiratory Syncytial Virus
April 20, 2022
Bavarian Nordic’s MVA-BN RSV Receives the US FDA’s Breakthrough Therapy Designation for Prevention of Respiratory Syncytial Virus
February 14, 2022
Bavarian Nordic Plans to Initiate P-III Trial of Respiratory Syncytial Virus Candidate MVA-BN
December 6, 2021
PharmaShots Weekly Snapshot (September 23-27, 2019)
September 30, 2019
Back to Home
Incisive News in 3 Shots.
First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2023 PharmaShots - All Rights Reserved.